• Aaloke Mody, Annette H Sohn, Collins Iwuji, Rayner K J Tan, Francois Venter, and Elvin H Geng.
• Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: aaloke.mody@wustl.edu.
• Lancet. 2024 Feb 3; 403 (10425): 471492471-492.

AbstractThe global HIV response has made tremendous progress but is entering a new phase with additional challenges. Scientific innovations have led to multiple safe, effective, and durable options for treatment and prevention, and long-acting formulations for 2-monthly and 6-monthly dosing are becoming available with even longer dosing intervals possible on the horizon. The scientific agenda for HIV cure and remission strategies is moving forward but faces uncertain thresholds for success and acceptability. Nonetheless, innovations in prevention and treatment have often failed to reach large segments of the global population (eg, key and marginalised populations), and these major disparities in access and uptake at multiple levels have caused progress to fall short of their potential to affect public health. Moving forward, sharper epidemiologic tools based on longitudinal, person-centred data are needed to more accurately characterise remaining gaps and guide continued progress against the HIV epidemic. We should also increase prioritisation of strategies that address socio-behavioural challenges and can lead to effective and equitable implementation of existing interventions with high levels of quality that better match individual needs. We review HIV epidemiologic trends; advances in HIV prevention, treatment, and care delivery; and discuss emerging challenges for ending the HIV epidemic over the next decade that are relevant for general practitioners and others involved in HIV care.Copyright © 2024 Elsevier Ltd. All rights reserved.

22 keywords...

hide…